ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

CEMI: Chembio Diagnostics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

CHEMBIO DIAGNOSTICS INC (OTCBB)
CEMI	0.32	N/A	(N/A%)	Vol. 0	N/A ET

CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.

General Information

CHEMBIO DIAGNOS

3661 Horseblock Road Medford, - 11763 Phone: 631-924-1135 Fax: +1 631 924 6033 Web: www.chembio.com Email: info@chembio.com

Industry	MED PRODUCTS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	N/A

Price and Volume Information

Zacks Rank
Yesterday's Close	0.32
52 Week High	0.39
52 Week Low	0.08
Beta	1.01
20 Day Moving Average	375,214.00
Target Price Consensus	N/A

% Price Change
4 Week	11.70
12 Week	86.11
YTD	204.54

% Price Change Relative to S&P 500
4 Week	10.50
12 Week	75.46
YTD	152.05

Share Information
Shares Outstanding (millions)	61.94
Market Capitalization (millions)	20.75
Short Ratio	0.00
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	N/A
Current Year EPS Consensus Estimate	N/A
Estimated Long-Term EPS Growth Rate	N/A
Next EPS Report Date	N/A

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	N/A
30 Days Ago	N/A
60 Days Ago	N/A
90 Days Ago	N/A

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-%
vs. Previous Quarter	-%

Sales Growth
vs. Previous Year	24.12%
vs. Previous Quarter:	29.34%

Price Ratios
Price/Book	8.47
Price/Cash Flow	-
Price / Sales	1.63

ROE
09/30/09	-19.29
06/30/09	-39.00
03/31/09	-52.80

ROA
09/30/09	-7.91
06/30/09	-16.70
03/31/09	-24.45

Current Ratio
09/30/09	-
06/30/09	1.58
03/31/09	1.54

Quick Ratio
09/30/09	-
06/30/09	0.98
03/31/09	0.86

Operating Margin
09/30/09	-3.67
06/30/09	-8.51
03/31/09	-13.21

Net Margin
09/30/09	-
06/30/09	-8.49
03/31/09	-13.08

Pre-Tax Margin
09/30/09	-
06/30/09	-8.49
03/31/09	-13.08

Book Value
09/30/09	-
06/30/09	0.04
03/31/09	0.04

Inventory Turnover
09/30/09	-
06/30/09	5.07
03/31/09	4.86

Debt-to-Equity
09/30/09	-
06/30/09	0.02
03/31/09	0.02

Debt to Capital
09/30/09	-
06/30/09	2.39
03/31/09	2.16


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research